AC Immune (NASDAQ:ACIU) Announces Earnings Results

AC Immune (NASDAQ:ACIU - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.03, Zacks reports. The business had revenue of $1.43 million during the quarter, compared to the consensus estimate of $0.74 million.

AC Immune Stock Down 3.5 %

NASDAQ:ACIU traded down $0.08 during mid-day trading on Monday, hitting $2.21. 195,916 shares of the stock traded hands, compared to its average volume of 330,957. The business's 50-day moving average price is $2.61 and its 200 day moving average price is $2.98. The company has a market cap of $218.66 million, a PE ratio of -4.80 and a beta of 1.23. AC Immune has a 12-month low of $2.19 and a 12-month high of $4.98.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of AC Immune in a research note on Friday.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.